Systemic Chemotherapy With FOLFOX in Metastatic Grade 1/2 Neuroendocrine Cancer

Molecular and Clinical Oncology - United Kingdom
doi 10.3892/mco.2016.1097
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Spandidos Publications

Related search

FOLFOX as Second-Line Chemotherapy in Patients With Pretreated Metastatic Pancreatic Cancer From the FIRGEM Study

BMC Cancer
Cancer ResearchOncologyGenetics
2014English

Gastric Adenocarcinoma Is Concurrent With Metastatic Neuroendocrine Cancer Treated With Nivolumab and Chemotherapy: A Case Report

Molecular and Clinical Oncology
Cancer ResearchOncology
2018English

FBXW4 Acts as a Protector of FOLFOX-Based Chemotherapy in Metastatic Colorectal Cancer Identified by Co-Expression Network Analysis

Frontiers in Genetics
GeneticsMolecular Medicine
2020English

A Phase II Study of Modified FOLFOX as First-Line Chemotherapy for Metastatic Gastric Cancer in Elderly Patients With Associated Diseases

Gastric Cancer
Cancer ResearchMedicineOncologyGastroenterology
2012English

Extending Survival With Chemotherapy in Metastatic Breast Cancer

Oncologist
Cancer ResearchMedicineOncology
2005English

Tumor Lysis Syndrome in Metastatic Colon Cancer After Single FOLFOX Cycle

International Journal of Case Reports and Images
2016English

Effects of Modified FOLFOX-6 Chemotherapy on Cellular Immune Function in Patients With Gastric Cancer

Oncology Letters
Cancer ResearchOncology
2018English

Chemotherapy of Metastatic Neuroendocrine Tumors With Aranose in Monoregimen and in Combination With Capecitabine and Temozolomide.

Malignant tumours
2015English

Metronomic Chemotherapy in Metastatic Breast Cancer

Novel Research in Sciences
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy